Navigation Links
Hard to Treat Diseases (HTDS.PK) Business Summary Update
Date:12/7/2009

SHENZHEN, China, Dec. 7 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com is using this opportunity to update its followers on the development of several previously announced events, which remain unresolved and or pending. These are Slavica Biochem's move into the Revenue Mode, Slavica's research expansion and pending EU Stem Cell Bank merger, HTDS' Africa Opportunity, HTDS' Pink Sheets "skull and bones" rankings, and the expected Q4 results.

HTDS and Slavica Biochem plan to start capitalizing on Slavica's research and move from purely Research and Development Mode into a Revenue Mode. Slavica Biochem wants to take full advantage of its research achievements. Its management foresees the first revenues commencing in 2010.

HTDS management also continues due diligence with the EU stem cell company regarding the merger discussions. In the light of these discussions, Slavica is exploring an opportunity to either commence its own stem cell bank, or in a capacity as a consultant - advisor to other European companies venturing in the stem cell marketplace. Both options will afford the company with an opportunity to generate substantial revenues without any dilution.

HTDS management is also exploring the options of expanding Slavica's research activity. This newly discussed project focuses on the methodplogy for treatment of damaged articular cartilage, namely, this medical process, which consists of autologous implantation of in-vitro cultivated chondrocytes (the cartilage-forming cells). This new technique is one of the most important orthopaedic achievements of this century. See Pink Sheets Filing November 24 2009 http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=26604

The research team from Slavica
'/>"/>

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain
2. New study finds barriers to pain treatment in children with sickle cell disease
3. Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease
4. New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer
5. New Gene Findings Will Help Guide Treatment in Infant Leukemia
6. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
7. Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care
8. Epilepsy patients caught in treatment gap are not getting state-of-the-art care
9. Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations
10. Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance
11. NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 30, 2015 , ... Zaca Life has created Recovery Chewable ... water needed, the refreshing berry-flavored tablets are the perfect travel companion. , “We ... that may help with body detoxification, protection and hydration,” said Mark Aleks, Zaca ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association (ATA) ... Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract ... take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... 2015 , ... The Beryl Institute announces its sixth annual ... Patient Experience Institute, these offerings reinforce the commitment to help frame and expand ... the experience movement, and provide information and research to support expanded focus and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research ... Patient Registry Act of 2015’. The bill was introduced in Congress yesterday by ... Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
... Mesa Laboratories, Inc. (Nasdaq: MLAB ), a supplier ... applications, today announced the appointment of Dr. John J. Sullivan ... R. Schmieder, who has been the CEO since founding the ... and resigning his positions of CEO and Treasurer, but will ...
... Corporation (Nasdaq: IRIX ) today reported its financial ... January 3, 2009.Revenues for the fourth quarter of 2008 were ... for the fourth quarter of 2007. The company,s net ... the fourth quarter of 2008 compared with a loss of ...
... , Loss of thinking power is a fear ... in a budding industry for brain training products exercises ... which in 2007 generated $80 million in the United States ... participants must complete a series of daily exercises such as ...
... Washington University School of Medicine in St. Louis have ... damage in humans with no signs of mental impairment. ... study participants with lower levels of a substance known ... fluid (CSF) had reduced whole brain volumes, suggesting that ...
... for others involved in tumor development , , TUESDAY, March 10 ... much lower risk of developing pancreatic cancer, a finding that ... , The study, by researchers at the Dana-Farber ... blood type and the disease, which is diagnosed in about ...
... that permits precise tuning of a gene,s expression in a ... of the gene,s role in normal and abnormal cellular function. ... negative feedback loop in the synthetic gene circuit, a concept ... by scientists at The University of Texas M. D. Anderson ...
Cached Medicine News:Health News:Mesa Labs Announces the Appointment of New CEO 2Health News:Mesa Labs Announces the Appointment of New CEO 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:Can mental training games help prevent Alzheimer's? 2Health News:Brain damage found in cognitively normal people with Alzheimer's marker 2Health News:Brain damage found in cognitively normal people with Alzheimer's marker 3Health News:Study Links Blood Type and Pancreatic Cancer 2Health News:Synthetic gene circuit allows precise dosing of gene expression 2Health News:Synthetic gene circuit allows precise dosing of gene expression 3
(Date:7/29/2015)... July 29, 2015  Unilife Corporation ("Unilife" or the ... developer, manufacturer and supplier of injectable drug delivery systems, ... that provides the Company with flexibility and control to ... has signed an equity purchase agreement for up to ... a Chicago -based institutional investor, which ...
(Date:7/29/2015)... 2015  Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2015 on Wednesday, August 5, 2015, after the close of ... executive officer, will host a conference call to review the ... Time (PT). The press release and a ... through a link that is posted on the home page ...
(Date:7/29/2015)... Calif. , July 29, 2015 Daiichi ... Daiichi Sankyo Group, announced today that The New ... results demonstrating that the investigational drug, PLX3397, an oral ... patients with tenosynovial giant cell tumor (TGCT), a rare, ... Following phase 1 dose-escalation, which evaluated the ...
Breaking Medicine Technology:Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
MBP's extra long 200 L pipet tip will reach the bottom of large tubes and vials, preventing your pipettor from contacting the sample container....
... is an immunometric ('sandwich') EIA for ... human serum or plasma. LH in ... monoclonal anti-LH antibodies directed at different ... magnetic particles and the other is ...
... is an HPLC system designed to provide ... levels and aid in the comprehensive identification ... results for glycemic control., ,The A1c assay ... with the accuracy of boronate affinity columns. ...
... of the fastest blood gas ... care situations on the market. ... lung function testing. The ... quick and reliable assessment of ...
Medicine Products: